THE ABSENCE OF SIGNIFICANT BILIARY-EXCRETION OF ANTIPYRINE OR ITS METABOLITES IN HUMANS

被引：10

作者：

WISSEL, PS

KAPPAS, A

机构：

来源：

关键词：

D O I：

10.1038/clpt.1987.14

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：85 / 87

页数：3

共 14 条

[1] AARBAKKE J, 1978, ACTA PHARM TOXICOL, V42, P64
[2] ADAMSON RH, 1973, INT ENCY PHARM THERA, P895
[3] HIGUCHI T, 1978, GANN, V69, P753
[4] MONOGENIC CONTROL OF VARIATIONS IN ANTIPYRINE METABOLITE FORMATION - NEW POLYMORPHISM OF HEPATIC DRUG OXIDATION
PENNO, MB
VESELL, ES
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (06) : 1698 - 1709
[5] ROCULAND M, 1980, CLIN PHARMACOKINETIC, P71
[6] IMPAIRMENT OF DRUG-METABOLISM IN PATIENTS WITH LIVER CANCER
SOTANIEMI, EA
PELKONEN, RO
MOKKA, RE
HUTTUNEN, R
VILJAKAINEN, E
[J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1977, 7 (04) : 269 - 274
[7] FURTHER OBSERVATIONS ON RELATIONSHIPS BETWEEN ANTIPYRINE HALF-LIFE, CLEARANCE AND VOLUME OF DISTRIBUTION - AN APPRAISAL OF ALTERNATIVE KINETIC-PARAMETERS USED TO ASSESS THE ELIMINATION OF ANTIPYRINE
SULTATOS, LG
DVORCHIK, BH
VESELL, ES
SHAND, DG
BRANCH, RA
[J]. CLINICAL PHARMACOKINETICS, 1980, 5 (03) : 263 - 273
[8] TENISSEN MWE, 1983, J CHROMATOGR, V278, P367
[9] VESELL ES, 1984, FED PROC, V43, P2342
[10] VESELL ES, 1975, CLIN PHARMACOL THER, V18, P259